Key Insights

Highlights

Success Rate

82% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 52/100

Termination Rate

18.2%

2 terminated out of 11 trials

Success Rate

81.8%

-4.7% vs benchmark

Late-Stage Pipeline

36%

4 trials in Phase 3/4

Results Transparency

0%

0 of 9 completed with results

Key Signals

82% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (5)
P 2 (1)
P 3 (3)
P 4 (1)

Trial Status

Completed9
Terminated2

Trial Success Rate

81.8%

Benchmark: 86.5%

Based on 9 completed trials

Clinical Trials (11)

Research Network

Activity Timeline